Nishio et al., 2014 - Google Patents
Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitorNishio et al., 2014
View HTML- Document ID
- 6825453655167161592
- Author
- Nishio H
- Yaguchi T
- Sugiyama J
- Sumimoto H
- Umezawa K
- Iwata T
- Susumu N
- Fujii T
- Kawamura N
- Kobayashi A
- Park J
- Aoki D
- Kawakami Y
- Publication year
- Publication venue
- British journal of cancer
External Links
Snippet
Background: Although T-cell immunity is thought to be involved in the prognosis of epithelial ovarian cancer (EOC) patients, immunosuppressive conditions hamper antitumour immune responses. Thus, their mechanisms and overcoming strategies need to be investigated …
- 230000001506 immunosuppresive 0 title abstract description 62
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nishio et al. | Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor | |
Ma et al. | Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy | |
Xiao et al. | DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation | |
Zheng et al. | TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer | |
Song et al. | Low-dose IFNγ induces tumor cell stemness in tumor microenvironment of non–small cell lung cancer | |
Liu et al. | Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions | |
Zhang et al. | CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer | |
Wu et al. | IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer | |
Shalapour et al. | Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy | |
Baghdadi et al. | Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells | |
Huynh et al. | CD 90+ stromal cells are the major source of IL‐6, which supports cancer stem‐like cells and inflammation in colorectal cancer | |
van der Zee et al. | IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDHhi/CD126+ stem-like component and reduces tumor burden | |
Ganguly et al. | Secretory mucin 5AC promotes neoplastic progression by augmenting KLF4-mediated pancreatic cancer cell stemness | |
Cao et al. | BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity | |
Agarwal et al. | G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation | |
Landsberg et al. | Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation | |
Shen et al. | IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases | |
Cocco et al. | Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma | |
Dai et al. | Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling | |
Tattevin et al. | Enhanced indoleamine 2, 3-dioxygenase activity in patients with severe sepsis and septic shock | |
Mao et al. | Increased tumor-infiltrating CD45RA− CCR7− regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress | |
Micucci et al. | HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma | |
Wang et al. | Upregulation of T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) in monocytes/macrophages associates with gastric cancer progression | |
Liu et al. | CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer | |
Timperi et al. | IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer |